Research progress on the pathogenesis of interstitial lung disease induced by Trastuzumab deruxtecan,an antibody-drug conjugate targeting HER2

VernacularTitle:靶向HER2的抗体偶联药德曲妥珠单抗诱导的间质性肺病研究进展
Author: Qing-Yue LIN ¹ ; Wei CHEN ; Xin-Lian PEI ; Wei ZOU ; Yan ZHANG
Author Information

1. 解放军联勤保障部队第900医院肿瘤科,福建福州 350025
Keywords: antibody-drug conjugate; Trastuzumab deruxtecan; drug-induced interstitial lung disease; pathogenesis
From: Medical Journal of Chinese People's Liberation Army 2024;49(12):1452-1459
CountryChina
Language:Chinese
Abstract: Trastuzumab deruxtecan(T-DXd)is a new generation of antibody-drug conjugate targeting human epidermal growth factor receptor 2.It has strong antitumor effects and has been recommended by many authoritative guidelines at home and abroad.Drug-induced interstitial lung disease(DILD)is one of the common adverse reactions and causes of death of T-DXd and is an important factor limiting its clinical application.The pathogenesis of DILD induced by T-DXd is still unclear,and the mainstream view holds that it may be related to the non-target-dependent uptake of the drug.Glucocorticoids are an important treatment method for DILD,and other alternative drugs still lack clinical effectiveness evidence.The research progress on the pathogenesis of T-DXd induced DILD was summarized in this review,aiming to provide new ideas for the prevention and treatment of DILD.